Matthew Ellis (@mattellisduke) 's Twitter Profile
Matthew Ellis

@mattellisduke

ID: 3806178743

calendar_today28-09-2015 18:03:16

107 Tweet

64 Followers

5 Following

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

excited about to learning events upcoming. Explore Transplant training the summer & Duke Transplant Summit in October 2018. Great teaching/learning opportunities. #askasn

excited about to learning events upcoming.  Explore Transplant training the summer & Duke Transplant Summit in October 2018.  Great teaching/learning opportunities. #askasn
Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

At duke, we use it de novo & in switch protocols. works great both ways, but different considerations when used in these different contexts. #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

our de novo use of bela is exclusively outside of research. de novo use is with campath induction & sirolimus maintenance. no steroids. not what the trials used. #askasn

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

no FDA indiction for use outside of kidney transplant as increased liver rejections. never trialed in heart or lung, but makes sense as they really like to run tacro troughs high. #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

emory uses bela, tacro, MPA + steroids & then drops the tacro after 6 (or 9 months) to address the early rejections seen in the trials. we us campth to avoid those early rejections. #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

the rejections seen in the BENEFIT/EXT were usually early, tended to be severe, but responded nicely to treatment. rejection rates thereafter non existent. GFR better @ one & seven year follow up. #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

infection rates similar to calcineurin inhibitor regimens (both in published literature + in our experience). we use sirolimus for this reason. #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

agree that emory uses the early tacro to prevent rejections. they were not using T cell depletion (I don't think) for induction. #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

not sure it refutes the rejection = more later loss, but the bela group in the extension of the BENEFIT trial did not have any more graft loss & GFR was better! #AskASN

Matthew Ellis (@mattellisduke) 's Twitter Profile Photo

follow up for up to 10 years, but 7 was the mean. need to confirm the GFR difference but on the order of 20mL/min delta (don't quote this number yet!) #AskASN